戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sal apoptosis in rats with H. pylori-induced gastropathy.
2 coxib for reducing the risk of NSAID-induced gastropathy.
3 hes and may clarify the etiology of diabetic gastropathy.
4 y a key role in the pathogenesis of diabetic gastropathy.
5 idal anti-inflammatory drug [NSAID])-induced gastropathy.
6 s evaluated for efficacy in preventing NSAID gastropathy.
7 cally different lactacystin, prevented NSAID gastropathy.
8 sing enteropathy secondary to a hypertrophic gastropathy.
9 trointestinal bleeding and/or protein-losing gastropathy.
10 gastroprotective agent against NSAID-induced gastropathy.
11 ls, which play a pathogenic role in inducing gastropathy.
12 up and 8 in the sclerotherapy group), portal gastropathy (1 patient in each group), and gastric lipom
13 diatric endoscopists are alerted to prolapse gastropathy, a more accurate description of an old and p
14  new molecular and mechanistic basis for PHT gastropathy and provide a new therapeutic modality for p
15 ally believed to be responsible for diabetic gastropathy and the underlying impairments in gastric em
16 of proteasome inhibitors in preventing NSAID gastropathy and their potency in inhibiting intracellula
17 sly used to establish the incidence of NSAID gastropathy, and also information on patient risk factor
18 sociated with a declining incidence of NSAID gastropathy, and, if so, what measures may have caused t
19 ed for treatment failures due to symptomatic gastropathy; and Strategy 2-safer, more expensive NSAID
20     These declines in the incidence of NSAID gastropathy are likely to continue.
21  secondary prophylaxis), portal hypertensive gastropathy, ascites, hepatorenal syndrome, spontaneous
22 pful in the treatment of hypertensive portal gastropathy but not gastric vascular ectasias.In the are
23 ary strategies to reduce the risk of serious gastropathy caused by traditional nonsteroidal anti-infl
24 ffer from gastric neuromuscular dysfunction (gastropathy) causing symptoms ranging from postprandial
25 H signalling that might be associated with a gastropathy clinically overlapping with Menetrier diseas
26                    The risk of serious NSAID gastropathy has declined by 67% in these cohorts since 1
27        Proteasome inhibitors prevented NSAID gastropathy if administered from 0 to 12 hours before in
28                          Portal hypertensive gastropathy impairs extracellular signal-regulated kinas
29                                Thus diabetic gastropathy in mice reflects an insulin-sensitive revers
30           H. felis can induce a hypertrophic gastropathy in the C57BL/6 genotype; loss of one p53 all
31 y, 3g protected against indomethacin-induced gastropathy in vivo by inhibiting MMP-9.
32                    Portal hypertensive (PHT) gastropathy is a frequent, serious complication of liver
33 dal antiinflammatory drug (NSAID)-associated gastropathy is a major cause of hospitalization and deat
34  from ectopic varices or portal hypertensive gastropathy is also possible.
35            Bleeding from portal hypertensive gastropathy or ectopic varices is less common.
36  of preexisting varices, portal hypertensive gastropathy, or ascites.
37 al hypertension, namely, portal hypertensive gastropathy (PHG) and gastric vascular ectasia (GVE), to
38 ct complications such as portal hypertensive gastropathy (PHG) and portal hypertensive polyps (PHPs).
39 as well as hyperplastic polyps, hyperplastic gastropathy, postendoscopic resection for gastric malign
40 iduals from a family with autosomal dominant gastropathy resembling Menetrier disease, a premalignant
41 ce develop gastric ulcers and a hypertrophic gastropathy resembling Menetrier's disease.
42 oidal anti-inflammatory drug (NSAID)-induced gastropathy with mechanistic details.